Not on the insulin program thats for sure! Its a mix and the stock has doubled off the lows just a few months ago.
I think HyQ looks like a great product though Baxter was cautious in launch expectations for 2012 (they need to build capacity if they really expect to gain market share because of it and they aren't just yet).
The Herceptin sub-q data seem good enough for approval. No reason to not think MabThera sub-q results won't be good as well. On the negatives Roche scaled back their partnership with them.
I really like the Viropharma deal too.
Their own programs I don't like the Insulin and doubt hylenex will amount to anything. Their pancreatic cancer program sounds interesting in theory and data could come relatively quick. I don't know how to handicap/value the cellulite program could be big but I wouldn't put much value in it at this point.
Sorry for the long (non?) answer. I like to try and present things balanced and let people decide for themselves.
One thing to keep in mind this is a (relatively) small financing given the share count. I can't really fault them for raising money given their cash situation. I just think they wouldn't have done so if they thought they could get any descent up-front money for their insulin program. Lets just hope they don't waste more money on it!
Market Data 
Markets 
AI
